| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
232,140,000 |
| Market
Cap: |
1.80(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.23 - $9.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ardelyx is a biopharmaceutical company focused on discovering, developing and commercializing medicines. This includes adult patients with irritable bowel syndrome with constipation (IBS-C), adult patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and adult patients with CKD and/or heart failure with elevated serum potassium, or hyperkalemia. Co.'s product pipeline includes among other, IBSRELA, a sodium hydrogen exchanger 3 inhibitor for the treatment of IBS-C in adults; and XPHOZAH, which is a medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
585,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,011,778 |
| Total People Bought |
0 |
0 |
0 |
7 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
766,409 |
1,189,266 |
1,315,394 |
1,951,649 |
| Total Sell Value |
$6,577,948 |
$9,083,370 |
$9,535,666 |
$10,165,404 |
| Total People Sold |
8 |
8 |
8 |
8 |
| Total Sell Transactions |
18 |
37 |
59 |
102 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Jacobs Jeffrey W |
Chief Scientific Officer |
• – – |
2021-08-03 |
4 |
OE |
$0.54 |
$5,400 |
D/D |
10,000 |
134,051 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2021-08-03 |
4 |
D |
$1.64 |
$246,563 |
D/D |
(150,343) |
332,303 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2021-08-03 |
4 |
OE |
$0.54 |
$144,662 |
D/D |
267,892 |
482,646 |
|
- |
|
| Bertrand William C Jr |
Director |
– • – |
2021-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,891 |
83,549 |
|
- |
|
| Rodgers Richard J |
Director |
– • – |
2021-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
9,917 |
87,527 |
|
- |
|
| Lundberg Jan M |
Director |
– • – |
2021-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,181 |
42,799 |
|
- |
|
| Jacobs Jeffrey W |
Chief Scientific Officer |
• – – |
2021-06-15 |
4 |
AS |
$7.29 |
$54,659 |
D/D |
(7,500) |
124,051 |
|
-84% |
|
| Jacobs Jeffrey W |
Chief Scientific Officer |
• – – |
2021-06-15 |
4 |
OE |
$0.54 |
$4,050 |
D/D |
7,500 |
131,551 |
|
- |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2021-05-28 |
4 |
S |
$7.22 |
$22,098 |
I/I |
(3,062) |
26,750 |
|
82% |
|
| Raab Michael |
President & CEO |
• • – |
2021-05-20 |
4 |
S |
$7.09 |
$17,960 |
D/D |
(2,534) |
214,754 |
|
81% |
|
| Rodriguez Susan |
Chief Commercial Officer |
• – – |
2021-05-20 |
4 |
S |
$7.09 |
$4,331 |
D/D |
(611) |
45,303 |
|
81% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2021-05-20 |
4 |
S |
$7.09 |
$1,113 |
I/I |
(157) |
29,812 |
|
81% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2021-05-20 |
4 |
S |
$7.09 |
$4,338 |
D/D |
(612) |
159,435 |
|
81% |
|
| Jacobs Jeffrey W |
Chief Scientific Officer |
• – – |
2021-05-20 |
4 |
S |
$7.09 |
$5,110 |
D/D |
(721) |
124,051 |
|
81% |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2021-05-20 |
4 |
S |
$7.09 |
$4,338 |
D/D |
(612) |
40,678 |
|
81% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2021-05-20 |
4 |
S |
$7.09 |
$3,601 |
D/D |
(508) |
102,912 |
|
81% |
|
| Blanks Robert |
See Remarks |
• – – |
2021-05-20 |
4 |
S |
$7.09 |
$4,338 |
D/D |
(612) |
106,954 |
|
81% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2021-04-06 |
4 |
AS |
$8.00 |
$40,000 |
D/D |
(5,000) |
160,047 |
|
-81% |
|
| Blanks Robert |
See Remarks |
• – – |
2021-04-06 |
4 |
AS |
$8.00 |
$41,304 |
D/D |
(5,163) |
107,566 |
|
-81% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2021-02-22 |
4 |
S |
$6.88 |
$1,328 |
I/I |
(193) |
29,969 |
|
-15% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2021-02-22 |
4 |
S |
$6.88 |
$4,212 |
D/D |
(612) |
165,047 |
|
-15% |
|
| Blanks Robert |
See Remarks |
• – – |
2021-02-22 |
4 |
S |
$6.88 |
$4,081 |
D/D |
(593) |
112,729 |
|
-15% |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2021-02-22 |
4 |
S |
$6.88 |
$4,185 |
D/D |
(608) |
41,290 |
|
-15% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2021-02-22 |
4 |
S |
$6.88 |
$3,469 |
D/D |
(504) |
103,420 |
|
-15% |
|
| Rodriguez Susan |
Chief Commercial Officer |
• – – |
2021-02-22 |
4 |
S |
$6.88 |
$4,205 |
D/D |
(611) |
45,914 |
|
-15% |
|
538 Records found
|
|
Page 8 of 22 |
|
|
0.29 (3.6%) 
